These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10967862)

  • 1. Medical treatment of hepatorenal syndrome.
    McCormick P; O'Keefe C; Docherty J
    Ir Med J; 1999; 92(7):422, 424. PubMed ID: 10967862
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatorenal syndrome: pathophysiology and management.
    Wadei HM; Mai ML; Ahsan N; Gonwa TA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1066-79. PubMed ID: 17699328
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatorenal syndrome: do the vasoconstrictors work?
    Leung W; Wong F
    Gastroenterol Clin North Am; 2011 Sep; 40(3):581-98. PubMed ID: 21893275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatorenal syndrome: a new therapeutic approach?].
    Gerbes AL; Gülberg V
    Z Gastroenterol; 1999 Sep; 37(9):983-5. PubMed ID: 10522370
    [No Abstract]   [Full Text] [Related]  

  • 7. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
    Gülberg V; Gerbes AL
    Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type-1 hepatorenal syndrome in patients with alcoholic end stage liver disease listed for liver transplantation: role of transjugular intrahepatic portosystemic stent shunt.
    Testino G; Ferro C
    Panminerva Med; 2007 Mar; 49(1):43-5. PubMed ID: 17468733
    [No Abstract]   [Full Text] [Related]  

  • 9. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Type 2 hepatorenal syndrome in a cirrhotic patient who underwent gastric cancer surgery].
    Kim JW
    Korean J Gastroenterol; 2010 Sep; 56(3):125-7. PubMed ID: 20847602
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
    Møller S; Bendtsen F; Henriksen JH
    Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatorenal syndrome: another piece of the puzzle.
    Ginès P; Guevara M; Perez-Villa F
    Hepatology; 2004 Jul; 40(1):16-8. PubMed ID: 15239080
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Guevara M; Rodés J
    Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: prognosis of hepatorenal syndrome--has it changed with current practice?
    Angeli P
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():44-6; discussion 47-8. PubMed ID: 15335400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome.
    Brensing KA; Textor J; Strunk H; Klehr HU; Schild H; Sauerbruch T
    Lancet; 1997 Mar; 349(9053):697-8. PubMed ID: 9078203
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of hepatorenal syndrome.
    McCormick PA; Donnelly C
    Pharmacol Ther; 2008 Jul; 119(1):1-6. PubMed ID: 18539334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular intrahepatic portosystemic stent shunt for hepatorenal syndrome and ascites.
    Wong F
    Digestion; 1998 Jul; 59 Suppl 2():41-4. PubMed ID: 9718418
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.